| Literature DB >> 29710852 |
Maria Kalimeri1, Francesca Leek2, Nan Xin Wang3, Huann Rong Koh4, Nicole C Roy5,6,7, David Cameron-Smith8,9,10, Marlena C Kruger11,12, Christiani Jeyakumar Henry13, John J Totman14.
Abstract
Insulin resistance (IR) is accompanied by increased areal or volumetric bone mineral density (aBMD or vBMD), but also higher fracture risk. Meanwhile, imbalances in bone health biomarkers affect insulin production. This study investigates the effect of IR on proximal femur and lumbar spine BMD, femoral neck bending, compressive and impact strength indices (Composite Strength Indices) and circulating levels of parathyroid hormone (PTH), C-telopeptide of Type I collagen (CTx-1) and 25(OH) Vitamin D₃, in a cohort of 97 healthy, non-obese, menopausal Chinese-Singaporean women. Lumbar spine aBMD was inversely associated with IR and dependent on lean body mass (LBM) and age. No such associations were found for vBMD of the third lumbar vertebra, aBMD and vBMD of the proximal femur, or circulating levels of PTH, CTx-1 and 25(OH) Vitamin D₃. Composite Strength Indices were inversely associated with IR and independent of LBM, but after adjusting for fat mass and age, this association remained valid only for the impact strength index. Composite Strength Indices were significantly lower in participants with a high degree of IR. Our findings on IR and Composite Strength Indices relationships were in agreement with previous studies on different cohorts, but those on IR and BMD associations were not.Entities:
Keywords: 25(OH) Vitamin D3; BMD; CTx-1; Composite Strength Indices; DXA; HOMA-IR; QCT; insulin resistance; parathyroid hormone (PTH)
Mesh:
Substances:
Year: 2018 PMID: 29710852 PMCID: PMC5981928 DOI: 10.3390/ijerph15050889
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
General characteristics of the total study population, “Low HOMA-IR” and “High HOMA-IR” groups and p values calculated by means of two-tailed t-tests between the two HOMA-IR groups.
| All Subjects | Low HOMA-IR | High HOMA-IR |
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (Group Size) | 96 | 60 | 36 | |||||||
|
| 60.70 | ± | 4.17 | 60.80 | ± | 4.30 | 60.50 | ± | 3.99 | 0.76 |
|
| 10.60 | ± | 6.04 | 10.20 | ± | 6.00 | 11.33 | ± | 6.15 | 0.39 |
|
| 55.90 | ± | 7.25 | 54.20 | ± | 6.26 | 58.78 | ± | 7.96 |
|
|
| 1.56 | ± | 0.05 | 1.56 | ± | 0.06 | 1.56 | ± | 0.05 | 0.94 |
|
| 22.90 | ± | 2.69 | 22.20 | ± | 2.44 | 24.03 | ± | 2.76 |
|
|
| 21.90 | ± | 4.96 | 20.86 | ± | 4.25 | 23.62 | ± | 5.62 |
|
|
| 31.59 | ± | 3.10 | 30.93 | ± | 2.88 | 32.69 | ± | 3.19 |
|
|
| 4.90 | ± | 0.46 | 4.80 | ± | 0.41 | 5.04 | ± | 0.51 |
|
|
| 6.20 | ± | 3.05 | 4.40 | ± | 1.21 | 9.25 | ± | 2.70 |
|
|
| 1.36 | ± | 0.71 | 0.93 | ± | 0.27 | 2.07 | ± | 0.64 |
|
p: significance level between Low HOMA-IR group and High HOMA-IR group. * p < 0.05.
Results of univariate and multivariate linear regression analysis between log10HOMA-IR and areal BMD (aBMD), volumetric BMD (vBMD), cortical bone ratio, Composite Strength Indices and blood markers.
| Unadjusted | Adjusted for LBM | Adjusted for LBM and Age | |||||||
|---|---|---|---|---|---|---|---|---|---|
| β |
| R2 | β |
| R2 | β |
| R2 | |
|
| |||||||||
|
| 0.054 | 0.604 | 0.003 | −0.064 | 0.540 | 0.113 | −0.064 | 0.531 | 0.162 |
|
| 0.000 | 0.997 | 0.000 | −0.096 | 0.365 | 0.075 | −0.096 | 0.359 | 0.111 |
|
| −0.053 | 0.605 | 0.003 | −0.199 | 0.050 | 0.172 | −0.199 |
| 0.189 |
|
| |||||||||
|
| |||||||||
| total | −0.062 | 0.549 | 0.004 | −0.144 | 0.185 | 0.057 | −0.144 | 0.177 | 0.097 |
| cortical | −0.047 | 0.648 | 0.002 | −0.103 | 0.350 | 0.027 | −0.103 | 0.346 | 0.050 |
| trabecular | 0.008 | 0.942 | 0.000 | −0.050 | 0.645 | 0.027 | −0.051 | 0.644 | 0.041 |
|
| |||||||||
| total | −0.015 | 0.888 | 0.000 | −0.097 | 0.367 | 0.055 | −0.098 | 0.358 | 0.095 |
| cortical | −0.044 | 0.671 | 0.002 | −0.103 | 0.349 | 0.029 | −0.103 | 0.337 | 0.083 |
| trabecular | 0.086 | 0.410 | 0.007 | −0.013 | 0.899 | 0.085 | −0.013 | 0.900 | 0.087 |
|
| |||||||||
|
| |||||||||
| total | −0.046 | 0.659 | 0.002 | −0.065 | 0.557 | 0.005 | −0.065 | 0.555 | 0.026 |
| cortical | 0.085 | 0.415 | 0.007 | 0.088 | 0.426 | 0.007 | 0.088 | 0.416 | 0.052 |
| trabecular | −0.019 | 0.855 | 0.000 | −0.022 | 0.840 | 0.000 | −0.023 | 0.837 | 0.031 |
| cort.vol/tot.vol | −0.093 | 0.369 | 0.009 | −0.114 | 0.301 | 0.012 | −0.114 | 0.293 | 0.054 |
|
| |||||||||
| total | −0.006 | 0.956 | 0.000 | −0.003 | 0.976 | 0.000 | −0.003 | 0.975 | 0.040 |
| cortical | −0.049 | 0.636 | 0.002 | −0.107 | 0.329 | 0.029 | −0.107 | 0.328 | 0.047 |
| trabecular | 0.040 | 0.703 | 0.002 | 0.023 | 0.835 | 0.004 | 0.023 | 0.836 | 0.015 |
| cort.vol/tot.vol | −0.070 | 0.500 | 0.005 | −0.048 | 0.666 | 0.009 | −0.048 | 0.666 | 0.016 |
|
| |||||||||
| trabecular | −0.140 | 0.175 | 0.020 | −0.187 | 0.087 | 0.037 | −0.187 | 0.075 | 0.120 |
|
| |||||||||
| CSI | −0.360 |
| 0.130 | −0.319 |
| 0.143 | −0.320 |
| 0.186 |
| BSI | −0.261 |
| 0.068 | −0.219 |
| 0.083 | −0.220 |
| 0.112 |
| ISI | −0.397 |
| 0.158 | −0.373 |
| 0.162 | −0.374 |
| 0.197 |
|
| |||||||||
| CTx-1 | 0.071 | 0.491 | 0.005 | 0.064 | 0.561 | 0.005 | 0.064 | 0.562 | 0.009 |
| 25(OH) Vitamin D3 | −0.002 | 0.984 | 0.000 | 0.028 | 0.798 | 0.007 | 0.028 | 0.798 | 0.024 |
| PTH | 0.109 | 0.291 | 0.012 | 0.030 | 0.780 | 0.062 | 0.030 | 0.780 | 0.069 |
LBM: lean body mass, β: standardized β-coefficient, p: significance level, R2: R-squared of the model; DXA: dual X-ray absorptiometry, QCT: quantitative computed tomography, cort.vol/tot.vol: cortical to total volume ratio; CSI: compression strength index, BSI: bending strength index, ISI: impact strength index, CTx-1: C-telopeptide of Type I collagen, PTH: parathyroid hormone. * p < 0.05.
Average values and standard deviations of parameters in “low HOMA-IR” and “high HOMA-IR” groups and p-values of two-tailed t-tests between the two groups.
| Low HOMA-IR Group | High HOMA-IR Group |
| |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| 0.64 | ± | 0.09 | 0.64 | ± | 0.08 | 0.978 | |
| 0.79 | ± | 0.11 | 0.78 | ± | 0.09 | 0.536 | |
| 0.87 | ± | 0.14 | 0.85 | ± | 0.13 | 0.404 | |
|
| |||||||
|
| |||||||
| total (g/cm2 K2HPO4) | 0.69 | ± | 0.11 | 0.66 | ± | 0.09 | 0.160 |
| cortical (g/cm2 K2HPO4) | 0.44 | ± | 0.11 | 0.42 | ± | 0.07 | 0.299 |
| trabecular (g/cm2 K2HPO4) | 0.24 | ± | 0.03 | 0.24 | ± | 0.04 | 0.377 |
|
| |||||||
| total (g/cm2 K2HPO4) | 0.75 | ± | 0.12 | 0.72 | ± | 0.10 | 0.257 |
| cortical (g/cm2 K2HPO4) | 0.46 | ± | 0.11 | 0.43 | ± | 0.08 | 0.169 |
| trabecular (g/cm2 K2HPO4) | 0.28 | ± | 0.03 | 0.29 | ± | 0.04 | 0.683 |
|
| |||||||
|
| |||||||
| total (mg/cm3 K2HPO4) | 312.58 | ± | 56.31 | 301.46 | ± | 36.53 | 0.294 |
| cortical (mg/cm3 K2HPO4) | 982.96 | ± | 113.00 | 998.28 | ± | 109.29 | 0.518 |
| trabecular (mg/cm3 K2HPO4) | 139.44 | ± | 19.42 | 134.77 | ± | 19.70 | 0.261 |
| cortical to total volume ratio | 0.21 | ± | 0.07 | 0.20 | ± | 0.05 | 0.266 |
|
| |||||||
| total (mg/cm3 K2HPO4) | 277.32 | ± | 59.01 | 270.17 | ± | 37.19 | 0.516 |
| cortical (mg/cm3 K2HPO4) | 926.69 | ± | 85.80 | 924.89 | ± | 76.49 | 0.918 |
| trabecular (mg/cm3 K2HPO4) | 133.29 | ± | 17.45 | 131.23 | ± | 17.76 | 0.580 |
| cortical to total volume ratio | 0.22 | ± | 0.24 | 0.18 | ± | 0.04 | 0.294 |
|
| |||||||
| trabecular (mg/cm3 K2HPO4) | 109.08 | ± | 24.55 | 99.86 | ± | 28.79 | 0.098 |
|
| |||||||
| CSI (g/(kg×m)) | 3.56 | ± | 0.61 | 3.16 | ± | 0.57 |
|
| BSI (g/(kg×m)) | 0.99 | ± | 0.22 | 0.89 | ± | 0.19 |
|
| ISI (g/(kg×m)) | 0.23 | ± | 0.04 | 0.20 | ± | 0.04 |
|
|
| |||||||
| CTx-1 (µg/L) | 0.51 | ± | 0.18 | 0.60 | ± | 0.30 | 0.067 |
| 25(OH)D3 (nmol/L) | 59.03 | ± | 14.65 | 60.33 | ± | 14.30 | 0.672 |
| PTH (pmol/L) | 4.65 | ± | 1.26 | 5.24 | ± | 3.30 | 0.218 |
p: significance level, cort.vol/tot.vol: cortical to total volume ratio; CSI: compression strength index, BSI: bending strength index, ISI: impact strength index. * p < 0.05.